Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Drug Deliv Transl Res. 2018 Aug;8(4):964–984. doi: 10.1007/s13346-017-0419-y

Fig. 8.

Fig. 8

Effects of DOX-free (Blank) NPs and 10% w/w DOX-loaded NPs (0.2 mg/mL) on expression of signaling proteins and MMPs/TIMP-1 in 7 day EaRASMC cultures following 30 min of incubation in parallel with cytokine injury. Shown are results for western blot analysis for JNK isoforms (A), active (p) JNK isoforms (B), total MMP2 (C) and TIMP-1 (E). Panel D shows a gel zymogram for MMP2 enzyme activity. In all cases, outcomes in the healthy controls (NP free RASMCs) and NP-treated, cytokine activated EaRASMCs are normalized to cytokine-activated EaRASMCs (treatment controls) (n = 3 per group; mean ± st. error). * denotes p < 0.05 compared to RASMC healthy cell controls and treatment controls respectively